Dyslipidaemia associated with the highly active antiretroviral therapy in aids patient: reversion after switching (stavudine to tenofovir and lopinavir/ritonavir to atazanavir/ritonavir)
AUTOR(ES)
Domingos, Hamilton, Cunha, Rivaldo Venâncio da, Paniago, Anamaria Mello Miranda
FONTE
Brazilian Journal of Infectious Diseases
DATA DE PUBLICAÇÃO
2007-04
RESUMO
Antiretroviral therapy has been associated with hyperlipidemia in AIDS patients. This case illustrates the classic metabolic effects associated to the HAART including protease inhibitors and/or stavudine. It was showed that the management of the HAART-associated dyslipidaemia with conventional antihyperlipidemic therapy may fail, being the switching strategy the best option.
Documentos Relacionados
- Factors associated with clinical, immunological and virological responses in protease-inhibitor-experienced brazilian children receiving highly active antiretroviral therapy containing Lopinavir-Ritonavir
- Lopinavir/ritonavir dosing during pregnancy in Brazil and maternal/infant laboratory abnormalities
- Interactions between Atazanavir-Ritonavir and Tenofovir in Heavily Pretreated Human Immunodeficiency Virus-Infected Patients
- Uso de lopinavir/ritonavir associado com ergotamina resultando em amputação de pé: comunicação breve
- Metabolic effects associated to the highly active antiretroviral therapy (HAART) in AIDS patients
